NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters declared that its board has approved a stock repurchase plan on Tuesday, April 24th 2018, which allows the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 18.2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

Waters Co. (NYSE:WAT) released its earnings results on Tuesday, April, 24th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.55 by $0.04. The medical instruments supplier had revenue of $530.70 million for the quarter, compared to the consensus estimate of $534.17 million. Waters had a return on equity of 25.80% and a net margin of 1.14%. The firm's quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.46 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.19.

16 analysts have issued 1-year price objectives for Waters' shares. Their forecasts range from $180.00 to $230.00. On average, they anticipate Waters' stock price to reach $204.7857 in the next year. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Ratings for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), PerkinElmer (PKI), Bio-Rad Laboratories, Inc. Class B (BIO.B), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

News stories about WAT stock have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Waters earned a media sentiment score of 0.15 on Accern's scale. They also assigned press coverage about the medical instruments supplier an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Waters' stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.26%), Jensen Investment Management Inc. (1.35%), Fenimore Asset Management Inc. (0.37%), Assenagon Asset Management S.A. (0.12%), Westpac Banking Corp (0.12%) and Bank of Montreal Can (0.11%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Baillie Gifford & Co., State of Alaska Department of Revenue, Hartford Investment Management Co., Westpac Banking Corp, Fenimore Asset Management Inc., Retirement Systems of Alabama and Copper Rock Capital Partners LLC. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Jensen Investment Management Inc., Hamilton Point Investment Advisors LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, DnB Asset Management AS, Bank of Montreal Can, Denali Advisors LLC and Fjarde AP Fonden Fourth Swedish National Pension Fund. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $197.15.

Waters has a market capitalization of $15.45 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]